Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy.

Kwak, Seo Young; Park, Sunhoo; Kim, Hyewon; Lee, Sun-Joo; Jang, Won-Suk; Kim, Min-Jung; Lee, SeungBum; Jang, Won Il; Kim, Ah Ra; Kim, Eun Hye; Shim, Sehwan; Jang, Hyosun; Miranda, Cristobal

Intestinal injury is observed in cancer patients after radiotherapy and in individuals exposed to radiation after a nuclear accident. Radiation disrupts normal vascular homeostasis in the gastrointestinal system by inducing endothelial damage and senescence. Despite advances in medical technology, the toxicity of radiation to healthy tissue remains an issue. To address this issue, we investigated the effect of atorvastatin, a commonly prescribed hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor of cholesterol synthesis, on radiation-induced enteropathy and inflammatory responses. We selected atorvastatin based on its pleiotropic anti-fibrotic and anti-inflammatory effects. We found that atorvastatin mitigated radiation-induced endothelial damage by regulating plasminogen activator inhibitor-1 (PAI-1) using human umbilical vein endothelial cells (HUVECs) and mouse model. PAI-1 secreted by HUVECs contributed to endothelial dysfunction and trans-endothelial monocyte migration after radiation exposure. We observed that PAI-1 production and secretion was inhibited by atorvastatin in irradiated HUVECs and radiation-induced enteropathy mouse model. More specifically, atorvastatin inhibited PAI-1 production following radiation through the JNK/c-Jun signaling pathway. Together, our findings suggest that atorvastatin alleviates radiation-induced enteropathy and supports the investigation of atorvastatin as a radio-mitigator in patients receiving radiotherapy.

ATORVASTATIN; INTESTINAL diseases; MONOCYTES; PLASMINOGEN activators; ANTICHOLESTEREMIC agents; REDUCTASE inhibitors; PLASMINOGEN

International Journal of Molecular Sciences, 2021, Vol 22, Issue 4, p1828

1661-6596

Academic Journal

10.3390/ijms22041828